Inpharma Weekly

, Volume 921, Issue 1, pp 3–4 | Cite as

Benzoporphyrin derivative could lead to new treatment for systemic diseases

  • Ian Mundell
Newsletter Article


Prospects for a more successful photodynamic therapy for cancer are increasing as early trials with benzoporphyrin derivative [BPD] produce encouraging results. This new drug has several advantages over the existing product, Photofrin®. But the therapeutic goals for BPD do not stop there. Researchers from Quadra Logic Technologies hope to develop a whole new mode of therapy for systemic diseases based on its properties. At the IBC conference, Drug Delivery and Targeting Systems, in London, UK, delegates were told of this latest development.


Systemic Lupus Erythematosus Photodynamic Therapy Photofrin Porfimer Sodium Recurrent Bladder Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Copyright information

© Adis International Ltd 1994

Authors and Affiliations

  • Ian Mundell

There are no affiliations available

Personalised recommendations